Recordati acquires drugmaker Italchimici

1 June 2016
mergers-acquisitions-big

Recordati (RECI: MI) says it has acquired 100% of the share capital of fellow Italian drugmaker Italchimici SpA from current owners Progressio SGR, manager of the fund Progressio Investimenti II, IDeA Capital Funds SGR, manager of the fund Fondo IDeA Efficienza Energetica e Sviluppo Sostenibile, and from managers of the company itself.

The value of the transaction is around 130 million euros ($145 million) and will be funded from existing liquidity. The signing and closing of the transaction took place at the same time.

Italchimici, with over 40 years of history and revenues in 2015 of 46 million euros, is a consolidated firm in the Italian pharmaceutical market with well-known products. The company offers therapeutic solutions mainly in the gastroenterological and respiratory areas which consist of both pharmaceutical products and food supplements and medical devices to improve the health and well-being of patients. The main brands in its extensive product portfolio are Reuflor, Peridon and Lacdigest in the gastroenterological offering and Aircort among the respiratory products.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical